Research Analysts’ Recent Ratings Updates for MacroGenics (MGNX)

Several brokerages have updated their recommendations and price targets on shares of MacroGenics (NASDAQ: MGNX) in the last few weeks:

• 11/10/2024 – MacroGenics was upgraded by analysts at StockNews.com from a “sell” rating to a “buy” rating.
• 11/7/2024 – MacroGenics was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating.
• 11/6/2024 – MacroGenics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
• 11/2/2024 – MacroGenics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/25/2024 – MacroGenics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.

MacroGenics Stock Performance

Shares of MacroGenics stock opened at $3.48 on Wednesday. MacroGenics, Inc. has a one year low of $2.95 and a one year high of $21.88. The company has a market capitalization of $218.40 million, a PE ratio of -2.20 and a beta of 2.08. The company has a 50-day simple moving average of $3.66 and a two-hundred day simple moving average of $4.33.

Institutional Investors Weigh In On MacroGenics

Institutional investors have recently bought and sold shares of the company. EntryPoint Capital LLC purchased a new stake in shares of MacroGenics during the 1st quarter valued at $40,000. CANADA LIFE ASSURANCE Co purchased a new stake in MacroGenics in the first quarter valued at about $52,000. XTX Topco Ltd acquired a new stake in MacroGenics in the third quarter worth about $37,000. China Universal Asset Management Co. Ltd. grew its stake in shares of MacroGenics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 4,707 shares during the last quarter. Finally, DRW Securities LLC purchased a new position in shares of MacroGenics in the 2nd quarter valued at approximately $56,000. 96.89% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.